Highlights from recent Life Science venture capital news.
Funding & Investment
July 25th, 2012 – Cambridge, MA
Bluebird bio Secures $60 Million in Oversubscribed Financing
bluebird bio, a leader in the development of innovative
gene therapies for severe genetic disorders, today announced the successful completion of a $60
million Series D financing. In this round, new investors Deerfield Partners, RA Capital, Ramius
Capital Group, and two undisclosed blue chip public investment funds joined existing investors
ARCH Venture Partners, Third Rock Ventures, TVM Capital, and Forbion Capital Partners. In
addition, Shire plc joined the round as a strategic investor.
July 24th, 2012 – Waltham, MA
Histogenics raises $49 million
Regenerative medicine company Histogenics Corporation, announced today the completion of a $49 million round of financing. The syndicate was led by Sofinnova Ventures with participation from additional new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund, L.P. Existing investors ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also participated in the financing. Proceeds will be used to complete the ongoing Phase 3 clinical program for lead product candidate NeoCart®, which is currently enrolling patients.
July 24th, 2012 – San Diego, CA
CoDa Therapeutics Completes $40 Million Series B Equity Financing
CoDa Therapeutics, Inc. announced today that it raised an additional $20M from RusnanoMedInvest (“RMI” a subsidiary of RUSNANO) in a second close of its Series B financing round. The transaction is the first investment under a joint investment agreement between RUSNANO and Domain Associates that was reached in March 2012. This brings the total Series B Round to nearly $40 million following the first close late last year. All current investors, including Domain Associates, GBS Ventures and BioPacificVentures participated.
July 25th, 2012 – Chicago, IL
Analyte Health Raises $22M for Online Medical Services
Who wants to go to the doctor to talk about sexually transmitted disease? Three venture firms are betting that many people would rather discuss STD questions over the phone.
Apex Venture Partners , Mohr Davidow Ventures and New World Ventures are backing Analyte Health Inc., an online medical-services company that helps people get tested for STDs and also provides them with access to doctors who answer questions by phone.
July 23rd, 2012 – Jerusalem, ISR
Chiasma Closes $38.5 Million Equity Financing
Chiasma (pronounced key-azma), Inc., a privately held biopharma company, announced that it closed a $38.5 million equity financing co-led by new investor Abingworth and current investor MPM Capital that also included investments from existing shareholders 7 Med Health Ventures, ARCH Venture Partners, F3 Ventures and Fredric Price, Chiasma’s Chairman & CEO.
July 23rd, 2012 – London, UK
Innovations invests in £17 million funding round for portfolio company, Cell Medica
Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), a leading technology commercialisation and investment group, has invested in a £17 million funding round in portfolio company Cell Medica, a clinical stage cell therapeutics business, enabling it to continue development of its immune reconstitution cell therapies in Europe and to launch new operations in Texas, US, focussing on cancer immunotherapy. Invesco Perpetual and the Cancer Prevention and Research Institute of Texas (CPRIT) also participated in the round.
July 25th, 2012 – Liverpool, UK
Evgen Raises £460K in Funding
Evgen, a Liverpool, UK-based company that develops a new cancer treatment, has raised £460k in funding. Backers include existing investors Enterprise Ventures (EV), the North West Fund for Biomedical, the Sarum Oncology Fund and a consortium of private individuals.
Led by CEO Dr Stephen Franklin, Evgen is developing Sulforadex, a synthetic pharmaceutical based on sulforaphane, a substance produced in the body after eating broccoli and other vegetables in the cabbage family, whose cancer protective benefits have been well documented.
July 26th, 2012 – London, UK
Clinithink Closes Investment Deal and Opens Doors for Healthcare
Spurred on by policy reforms in the US, investment in health IT continues to surge in 2012 as more and more healthcare providers continue to implement technology to improve patient care and reduce the cost of delivering medical services. Demonstrating the trend to invest in high-value health IT solutions is Clinithink, a UK-based healthcare software company which has successfully concluded a Series A funding round led by Vanguard Atlantic, a US-based equity firm focused on technology.
This Week In Venture Capital is brought to you by VM Index – Venture Capital made easier
VM Index is an online IT, Life Science, Biotech & Med Tech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.